Key result
Sitagliptin protects against renal damage in T2DM with CKD via reduced inflammation in animal models.
Why the study?
Does sitagliptin improve outcomes in Type 2 Diabetes Mellitus patients with chronic kidney disease?
Does sitagliptin improve outcomes in Type 2 Diabetes Mellitus patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
Sitagliptin is highlighted as a safe and effective treatment option for patients with type 2 diabetes and chronic kidney disease, with potential renoprotective effects.
The incidence of chronic kidney disease (CKD) in Type 2 Diabetes Mellitus patients accounts for 34,6–40% of cases. The importance of glycemic control for the prevention of kidney damage and progression of nephropathy in T2DM patients is proven in numerous studies. The presence of CKD significantly limits the choice of antidiabetic drugs and requires changes in dosages. Sitagliptin-DPP-4 inhibitor is approved for use at any stage of CKD. Clinical studies involving Sitagliptin provide a powerful base demonstrating the effectiveness and safety of the drug in CKD. The article presents the data of clinical and experimental studies indicating the protective role of Sitagliptin in the development of renal damage. The animal experiments revealed that the suppression of the activity of DPP-4 by Sitagliptin in kidneys leads to regression of renal damage, with reduced markers of inflammation and endothelial dysfunction.
No takes yet. Share an insight, caveat, or question.
I. A. Bonda (2017) conducted a review in Type 2 Diabetes Mellitus with chronic kidney disease. Sitagliptin was evaluated. Sitagliptin demonstrates a protective role against renal damage in type 2 diabetes mellitus with chronic kidney disease, with animal models showing regression of renal damage and reduced inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: